SARS-COV-2 Vaccinations in RMD patients

The EULAR Task Force on COVID-19 has updated the EULAR View-points on SARS-CoV-2 vaccination in patients with RMDs (December 2021).

The information addresses questions, including considerations regarding vaccination effectiveness and safety, the third vaccination dose, booster vaccination, combination with Influenza and Pneumococcus vaccination, among other frequently asked questions by people with RMDs.

EULAR President, Prof Annamaria Iagnocco, invites you to share the link with your axSpA community.

Other NEWS

ASIF Member Webinar Series

The potential to treat axSpA via the gut microbiome   Watch Dr …

Read More
ASAS Annual Meeting – Report

  ASAS Annual Meeting - Report Patient representatives from ASIF were invited …

Read More
ASIF Council Meeting, Copenhagen 29-31 May 2022

ASIF Council Meeting, Copenhagen 29-31 May 2022 We are delighted that …

Read More
Languages: